Related Experiment Video
Updated: Aug 13, 2026

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
Published on: March 16, 2016
[Abeta vaccine therapy for Alzheimer's disease]
1Department of vascular dementia research, National Institute for Longevity Sciences, NCGG.
Abstract:
In 1999, Schenk et al reported that vaccination of PDAPP-transgenic mice with synthetic Abeta42 in complete Freund's adjuvant showed markedly decrease of the amyloid burden in the brain. The second trial of vaccine, AN1792, for Alzheimer's patients was halted because of meningoencephalitis found in 6% of patients and one autopsy case was reported. Here, we comment the methods and the immunological mechanisms of Abeta vaccine therapy and discuss the pathological changes in the brain and side effects after AN1792 treatment. Furthermore, we present an oral Abeta vaccine therapy for Alzheimer's disease with the recombinant adeno-associated virus (AAV) vector that we developed.
Related Concept Videos
Alzheimer's Disease: Treatment
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease ll: Pathophysiology
Alzheimer Disease l: Introduction
Dementia l: Introduction
